The 2022 Access to Medicine Index finds that since the COVID-19 pandemic hit, more pharmaceutical companies have stepped up to make some of their products more widely accessible in low- and middle-income countries (LMICs). If the pandemic is to be a turning point in the fight for equitable access to medicine, companies must now scale their efforts to cover more products in their portfolios, and in a greater number of countries.

Index finds more pharma companies moving to address access to medicine. Will they now go further?
Related Articles
More stories in the same topic area.





